Drug Trial Radar · NCT06470763
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Jul 1, 2024
Primary completion
Jun 22, 2026
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- Anaveon AGIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
ANV600Drug
ANV600 administered by intravenous (IV) infusion
ANV600 + pembrolizumab (KEYTRUDA®)Drug
ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I dose escalation: Incidence of Dose Limiting Toxicities (DLT) with ANV600 single agent and in combination with pembrolizumab combination with pembrolizumabTime frame: Day 1 up to 24 months
- Phase I dose escalation: Frequency and severity of treatment-emergent adverse events (TEAEs) with ANV600 and in combination with pembrolizumabTime frame: Day 1 up to 24 months
- Phase II: Objective Response Rate (ORR) using RECIST v1.1Time frame: Day 1 up to 24 months
- Phase II: Duration of Response (DOR) using RECIST v1.1Time frame: Day 1 up to 24 months
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
Karmanos Cancer Institute
Detroit, Michigan
Fox Chase Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Institut Bergonie
Bordeaux, France
CEPCM - AP-HM Hopital de la Timone
Marseille, France
Oncopole Claudius Regaud, Toulouse
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF)
Frankfurt, Germany
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
Mainz, Germany
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)
Amsterdam, Netherlands
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
START Madrid CIOCC
Madrid, Spain
Clinica Universidad de Navarra - Pamplona
Pamplona, Spain
INCLIVA Foundation
Valencia, Spain
Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana
Bellinzona, Switzerland
Cantonal Hospital St Gallen
Sankt Gallen, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.